GlaxoSmithKline posts full-year 2009 profits up 20% as 4th qtr earnings leap 66%
UK-headquartered drugs giant GlaxoSmithKline reported that fourth-quarter 2009 earnings per share soared 66% to 32.1 pence, pushed higher by strong sales of swine flu vaccine. Net profit was £1.63 billion ($2.6 billion), compared £to 982 million a year earlier.
The, figures, which were released ahead of the company's results presentation this afternoon and just as today's filings were going live, also showed that full-year net profit was 20% higher at £5.5 billion. Sales rose 17% to £ 8.09 billion for the quarter, and were up 16% to £28.37 billion for the year. A full analysis of GSK's results will be posted tomorrow.
At 1215 GMT GSK shares were trading up 1.7% at 1,238 pence, in a lower London market. The stock has shown little net change in the last 12 months, and stand 0.3% above a year-ago levels.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze